🇺🇸 FDA

Company profile · Sponsor

Chiesi

Chiesi Farmaceutici S.p.A

E04721B · EMA pharma PARMA, IT
Pipeline
20
Drugs
0
Patents
0

Quick answer

Chiesi (E04721B) is a pharma company. headquartered in PARMA, IT. listed on EMA. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E04721B
Exchange EMA
Company type pharma
Headquarters PARMA, IT

Pipeline (20)

Search pipeline →

  1. CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI

    Chiesi

    Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis

    phase 3 small molecule active

    1 trial

  2. IMP Placebo, Comparator Placebo, Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension., CHF5993 pMDI (100) -152a

    Chiesi

    Uncontrolled Asthma

    phase 3 small molecule active

    1 trial

  3. Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

    Chiesi

    Fabry's disease

    phase 3 other active

    1 trial

  4. Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alpha (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease

    Chiesi

    Fabry disease (α-galactosidase A deficiency)

    phase 3 other active

    1 trial

  5. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  6. training kit, CHF1535 pMDI 100/6, CHF5993 pMDI-US

    Chiesi

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  7. 0.9% sodium chloride aqueous solution for IV infusion

    Chiesi

    Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  8. CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    Chiesi

    Mild to moderate asthma

    phase 2 small molecule active

    1 trial

  9. CHF6001 DPI

    Chiesi

    Asthma

    phase 2 small molecule active

    1 trial

  10. Cardiovascular safety assessment of Tanimilast in healthy volunteers

    Chiesi

    This is Phase I study to assess the effect on the heart rate (HR) and cardiovascular safety according to electrocardiographic monitoring (including QT and QTc intervals) of CHF6001(Tanimilast) administered with NEXThaler® device in healthy adult volunteers.

    phase 1 other active

    1 trial

  11. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the AeroChamber Plus® spacer, in healthy volunteers.

    Chiesi

    Asthma

    phase 1 other active

    1 trial

  12. Comparison of the study drug CHF 1535 formulated with two different propellants to learn about drug levels in blood and safety after inhalation, with and without the use of the Aerochamber Plus® spacer, in healthy volunteers.

    Chiesi

    Asthma and chronic obstructive pulmonary disease (COPD).

    phase 1 other active

    1 trial

  13. Effect of Erythromycin on the absorption, metabolism and elimination of CHF6001 in healthy volunteers

    Chiesi

    This study is a phase I trial to investigate the effect of inhibition of CYP3A4/5 by Erythromycin on the pharmacokinetics of CHF6001 in healthy volunteers.

    phase 1 other active

    1 trial

  14. Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.

    Chiesi

    Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

    phase 1 other active

    1 trial

  15. Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults

    Chiesi

    Pulmonary fibrosis

    phase 1 other active

    1 trial

  16. Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers.

    Chiesi

    Asthma

    phase 1 other active

    1 trial

  17. Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects

    Chiesi

    Chronic cough

    phase 1 other active

    1 trial

  18. Not applicable

    Chiesi

    Non-cystic fibrosis bronchiectasis

    phase 1 other active

    1 trial

  19. Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.

    Chiesi

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial

  20. Fostair 200 microgram/6 microgram per actuation pressurised inhalation solution, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

    Chiesi

    Asthma

    approved small molecule active

    1 trial

Frequently asked questions

What is Chiesi?

Chiesi (E04721B) is a pharma company. headquartered in PARMA, IT. listed on EMA. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Chiesi sponsor?

We track 20 ClinicalTrials.gov-linked programs for Chiesi, including CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI and 19 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Chiesi company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.